Collegium Pharmaceutical Inc (COLL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Collegium Pharmaceutical Inc (COLL) has a cash flow conversion efficiency ratio of 0.285x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($78.44 Million) by net assets ($274.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Collegium Pharmaceutical Inc balance sheet quality to measure how much of total assets are equity-financed.
Collegium Pharmaceutical Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Collegium Pharmaceutical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check COLL cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Collegium Pharmaceutical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Collegium Pharmaceutical Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
thyssenkrupp nucera AG & Co. KGaA
XETRA:NCH2
|
0.001x |
|
Chongqing Gas Grp Corp Ltd
SHG:600917
|
0.082x |
|
West China Cement Limited
F:WFG1
|
0.040x |
|
Nobia AB
ST:NOBI
|
-0.026x |
|
PROS Holdings Inc
NYSE:PRO
|
-0.149x |
|
Sinomach Automobile Co Ltd
SHG:600335
|
-0.072x |
|
Hagar hf
IC:HAGA
|
0.078x |
|
Jiangsu Favored Nanotechnology Co. Ltd. A
SHG:688371
|
N/A |
Annual Cash Flow Conversion Efficiency for Collegium Pharmaceutical Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Collegium Pharmaceutical Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see COLL market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $228.84 Million | $204.98 Million | 0.896x | -36.29% |
| 2023-12-31 | $195.43 Million | $274.75 Million | 1.406x | +120.50% |
| 2022-12-31 | $194.84 Million | $124.23 Million | 0.638x | +24.94% |
| 2021-12-31 | $202.93 Million | $103.56 Million | 0.510x | +1.06% |
| 2020-12-31 | $186.03 Million | $93.94 Million | 0.505x | +58.92% |
| 2019-12-31 | $87.43 Million | $27.78 Million | 0.318x | -82.82% |
| 2018-12-31 | $91.58 Million | $169.39 Million | 1.850x | +387.24% |
| 2017-12-31 | $104.08 Million | $-67.02 Million | -0.644x | -15.74% |
| 2016-12-31 | $134.91 Million | $-75.05 Million | -0.556x | -119.45% |
| 2015-12-31 | $85.07 Million | $-21.57 Million | -0.254x | -117.29% |
| 2014-12-31 | $-12.24 Million | $-17.95 Million | 1.466x | +149.51% |
| 2013-12-31 | $5.58 Million | $-16.53 Million | -2.961x | -- |
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more